Kymera Therapeutics (KYMR.US) was first covered by Oppenheimer, giving it an superior market rating, with a target price of $53.00.
Kymera Therapeutics(KYMR.US)获奥本海默首次覆盖，给予优于大市评级, 目标价53.00美元。
Kymera Therapeutics (KYMR.US) was first covered by Oppenheimer, giving it an superior market rating, with a target price of $53.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.